Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
News|Articles|September 18, 2026
Beyond the Data: Why Scientific Storytelling Will Define the Future of Medical Communications
Author(s)EVERSANA INTOUCH
Scientific storytelling is becoming a critical differentiator in Medical Affairs. Discover how leading organizations are moving beyond standalone assets and data-heavy communications to create connected scientific narratives, activate modern influence networks, and deliver more meaningful engagement with healthcare professionals.
Related to this article
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
4
Before You Sign with a New Hub Vendor, Ask These Four Questions
5